Regeneron Pharmaceuticals (NASDAQ:REGN) Receives Buy Rating from Canaccord Genuity Group

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)'s stock had its "buy" rating reaffirmed by Canaccord Genuity Group in a research report issued on Wednesday,Benzinga reports. They presently have a $850.00 target price on the biopharmaceutical company's stock. Canaccord Genuity Group's price target points to a potential upside of 50.95% from the stock's current price.

Several other analysts have also commented on REGN. Wells Fargo & Company lowered Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $700.00 to $580.00 in a report on Friday, May 30th. Morgan Stanley dropped their price objective on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a report on Thursday, July 10th. Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a report on Friday, May 30th. Citigroup dropped their price objective on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. Finally, Guggenheim reissued a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $837.61.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $1.54 during midday trading on Wednesday, hitting $563.10. 755,785 shares of the company were exchanged, compared to its average volume of 1,123,976. The firm has a market capitalization of $60.79 billion, a PE ratio of 14.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.33. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The business has a fifty day simple moving average of $543.18 and a two-hundred day simple moving average of $610.72. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm's revenue was down 3.7% on a year-over-year basis. During the same period last year, the business earned $9.55 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. TD Private Client Wealth LLC raised its position in Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 15 shares during the period. Adirondack Trust Co. raised its position in Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 18 shares during the period. Prestige Wealth Management Group LLC raised its position in Regeneron Pharmaceuticals by 23.2% in the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after purchasing an additional 19 shares during the period. Kingswood Wealth Advisors LLC raised its position in Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares during the period. Finally, Creative Financial Designs Inc. ADV raised its position in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after purchasing an additional 19 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.